About Ansa Biotechnologies
Ansa Biotechnologies is a company based in Berkeley (United States) founded in 2017 by Sebastian Palluk, Jared Ellefson, and Daniel Lin-Arlow.. Ansa Biotechnologies has raised $175.5 million across 8 funding rounds from investors including Mubadala, RA Capital and Northpond Ventures. Ansa Biotechnologies offers products and services including DNA Synthesis Service and Ansa On-Time Guarantee. Ansa Biotechnologies operates in a competitive market with competitors including Twist Bioscience, Nuclera Nucleics, Nutcracker Therapeutics, DNA Script and Sensible Biotechnologies, among others.
- Headquarter Berkeley, United States
- Founders Sebastian Palluk, Jared Ellefson, Daniel Lin-Arlow
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$175.5 M (USD)
in 8 rounds
-
Latest Funding Round
$54.4 M (USD), Series B
Oct 02, 2025
-
Investors
Mubadala
& 16 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ansa Biotechnologies
Ansa Biotechnologies offers a comprehensive portfolio of products and services, including DNA Synthesis Service and Ansa On-Time Guarantee. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables direct synthesis of complex DNA sequences up to 7.5 kb.
Ensures timely delivery of DNA orders or offers free service.
Unlock access to complete
Funding Insights of Ansa Biotechnologies
Ansa Biotechnologies has successfully raised a total of $175.5M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $54.4 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series B — $54.4M
- First Round First Round
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - Ansa Biotechnologies | Valuation | Cerberus Capital Management | |
| Jun, 2024 | Amount | Series A - Ansa Biotechnologies | Valuation |
investors |
|
| Apr, 2022 | Amount | Debt – Conventional - Ansa Biotechnologies | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ansa Biotechnologies
Ansa Biotechnologies has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Mubadala, RA Capital and Northpond Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Founded Year | Domain | Location | |
|
Early stage life sciences sectors focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Investment firm focused on finance and technology opportunities.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ansa Biotechnologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ansa Biotechnologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ansa Biotechnologies Comparisons
Competitors of Ansa Biotechnologies
Ansa Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Twist Bioscience, Nuclera Nucleics, Nutcracker Therapeutics, DNA Script and Sensible Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| domain | founded_year | HQ Location |
Desktop bioprinter for genes and proteins production is developed.
|
|
| domain | founded_year | HQ Location |
mRNA therapeutics are developed via proprietary biochip platforms.
|
|
| domain | founded_year | HQ Location |
Benchtop DNA printers for nucleic acid synthesis are developed.
|
|
| domain | founded_year | HQ Location |
Developer of mRNA technology for therapeutics and vaccines
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ansa Biotechnologies
Frequently Asked Questions about Ansa Biotechnologies
When was Ansa Biotechnologies founded?
Ansa Biotechnologies was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Ansa Biotechnologies located?
Ansa Biotechnologies is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Who is the current CEO of Ansa Biotechnologies?
Jason T Gammack is the current CEO of Ansa Biotechnologies.
Is Ansa Biotechnologies a funded company?
Ansa Biotechnologies is a funded company, having raised a total of $175.5M across 8 funding rounds to date.
What does Ansa Biotechnologies do?
Ansa Biotechnologies was founded in 2017 in Berkeley, United States. Operations are conducted in the biotechnology sector, where DNA synthesis is facilitated through enzyme-based methods. A chemical approach and next-generation technology are utilized, relying on polymerase-nucleotide conjugates to extend DNA molecules by one building block sequentially. Services are centered on advancing molecular synthesis capabilities in a research-oriented environment.
Who are the top competitors of Ansa Biotechnologies?
Ansa Biotechnologies's top competitors include Nuclera Nucleics, Twist Bioscience and Sensible Biotechnologies.
What products or services does Ansa Biotechnologies offer?
Ansa Biotechnologies offers DNA Synthesis Service and Ansa On-Time Guarantee.
Who are Ansa Biotechnologies's investors?
Ansa Biotechnologies has 17 investors. Key investors include Mubadala, RA Capital, Northpond Ventures, Altitude Life Science Ventures, and PEAK6.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.